Botanix Pharmaceuticals (ASX:BOT) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals Debt-to-Equity?

Botanix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Botanix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Botanix Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$45.39 Mil. Botanix Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Botanix Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Botanix Pharmaceuticals was 0.02. The lowest was 0.00. And the median was 0.01.

ASX:BOT's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Botanix Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Botanix Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals Debt-to-Equity Chart

Botanix Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

0.02

Botanix Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.02	-	-	-

Competitive Comparison of Botanix Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Botanix Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's Debt-to-Equity falls into.

Botanix Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Botanix Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	22.951
	=	0.00

Botanix Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	45.39
	=	0.00

Botanix Pharmaceuticals (ASX:BOT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Botanix Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Botanix Pharmaceuticals (ASX:BOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BXPHF:USA

Address

661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007

Website

https://www.botanixpharma.com

Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines